The LUVEN screening test method created by scientist of our company detects cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy.
The LUVEN technology allows to diagnose the disease at its early stages, thus, giving a chance to thousands of people to prevent its further development.
For more than 20 years the Ukrainian scientists have been developing a diagnostic method based on cyto-morphological and cyto-biophysical properties of the buccal epithelial cells. In 2004 at Fenix Cancer Research Center, they continued their research and, finally, came up and implemented an experimental method. A new method of biomaterial analysis allowed to establish a cancer diagnosis at its early stages and to assess predisposition to cancer. A great success in this medical field opened a door to new possibilities,including cancer prevention and therapy. The longstanding scientific research in this field culminated in development of The Luven diagnostic system.
Why is it critical to detect cancer in its early stage?
Around 10 mln people worldwide are annually diagnosed with cancer, with every third patient dying from it. One of the main reasons of such a high mortality rate is late diagnosis.
According to statistics:
This is why one should get a check-up as often as possible, thus preventing the disease progression.
Regardless of the rapid development of modern medicine and biology cancer, annually, takes millions of human lives. One cancer patient, worldwide, dies from this disease every 30 seconds.
The key to successful cancer treatment is early diagnosis.
Our History
The development of this method started in early 1983 at the research institute, chair for genetics. Based on the cellular theory by Rudolf Vichow, a team of scientists was working on a diagnostic method and studying buccal cells. Ms. Galina Shchukina, a genetic scientist and cytologist, was at the head of the scientific research. She conducted an in-depth study of scientific papers describing a new biophysical concept of the gene activity regulation based on the role of relationship between homologous chromosomes and genome. Together with Mr. Alexander Shchukin, a nuclear physicist, they invented an ion trap allowing to estimate bioelectric charge of cells. Further research and studies of this concept laid the basis for a new diagnostic method born in 2004, according to which any changes in the human body reflect on cells, including buccal epithelial cells. It was the first milestone in the development of LUVEN a unique diagnostic and treatment system. As of today, this method allowed to collect statistical data on tests of more than twenty thousand of patients.
Why is it lucrative?
Cancer research is an acute social problem, in view of this they cast a veil on profits of medical companies. However, in-vitro diagnostics, and particularly cancer diagnostics, is a huge and most rapidly developing sector, with the potential global market of DNA cancer tests worth about $20 bn.
Unlike the majority of projects involving ICO, our company has already completed 90% of the whole thing. The presale period starts on November 15 until December 6, 2017. The token sale is planned from January 15 to February 28, 2018.
토큰 소유자에게는 두 가지 기회가 있습니다.
Ethereum ERC20 표준 토큰.
1983
2004 년
2010
2014
2015
2016 - 2017
2017 년 9 월 - 10 월
2018 년 1 월
2018 년
2019 년
2020 년
2021
검증 됨 0%
주의. 확인되지 않은 회원은 실제로 팀원이 아닌 위험이 있습니다.
이 쿠폰은 쿠폰 제공자가 제공 한 정보 및 기타 공개적으로 제공되는 정보를 기반으로합니다. 토큰 판매 또는 교환 이벤트는 ICO 보유자와 전적으로 관련이 없으며 ICOholder는 이에 관여하지 않습니다 (기술 지원 또는 프로모션 포함). ICOholder와 관계가없는 사람들로부터 나열된 토큰 판매는 고객이 전반적인 토큰 부문에서 발생하는 활동을 추적하는 데 도움이되는 경우에만 표시됩니다. 이 정보는 귀하가 의지해야 할 조언에 해당하지 않습니다. 당사 사이트의 내용을 기반으로 한 조치를 취하거나 삼 가기 전에 전문가 또는 전문가의 자문을 구하거나 자신의 실사를 수행해야합니다. 토큰 획득과 관련하여 참가자가 입력 한 조건은 토큰과 ICO 소유자의 발행인이 그러한 토큰의 판매자가 아닙니다. ICO 소유자는 토큰 판매와 관련하여 제 3 자의 진술에 대해 법적 책임이 없으며 계약 위반에 대한 청구는 여기에 열거 된 토큰 발행 기관과 직접 체결해야합니다.
이 토큰 판매 또는 관련 인물의 성격, 적법성 또는 합법성에 대해 우려되는 점이 있으면 info@icoholder.com 에 문의하십시오. 귀하의 우려 사항에 대한 자세한 정보를 제공하십시오.